Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05549661
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:23.253815+00:00
Published At
2026-02-23T00:00:00+00:00
Record Updated At
2026-02-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Chronic Myelomonocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified", "Recurrent Atypical Chronic Myeloid Leukemia", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Myelodysplastic/Myeloproliferative Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-23"
protocolSection.identificationModule.nctId
"NCT05549661"
protocolSection.identificationModule.officialTitle
"Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Recurrent Atypical Chronic Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Myelodysplastic/Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.